Illumina Unveils TruSight Oncology 500 for Advanced Cancer Genomics

Leading DNA sequencing and genomics company Illumina Inc. has introduced TruSight Oncology 500 version 2 (TSO 500 v2), the next version of their flagship cancer research test. Comprehensive genomic profiling (CGP), which provides comprehensive molecular tumor patterns for therapy selection research and clinical trial eligibility, is vital for broadening access to precision medicine.

"TSO 500 is a trusted assay used by hundreds of researchers worldwide, and these enhancements deliver even greater value for customers with built-in HRD detection, faster turnaround time, and less tissue required," said Everett Cunningham, chief commercial officer of Illumina. "Customers need complete workflow solutions like this one to enable CGP more efficiently and at scale, ultimately advancing access to tumour profiling and cancer therapy research."

The upgraded assay offers streamlined sample-to-analysis workflows, sensitive variant calling, expanded biomarker profiling, and—for the first time—homologous recombination deficiency (HRD) detection powered by Myriad Genetics’ gold standard Genomic Instability Score (GIS) algorithm, included at no extra cost.

Also Read: The Future of Genomic Sequencing: Trends That Will Define the Next Decade

Early-access customer Weiyi Chen, PhD, technical director at siParadigm Diagnostic Informatics, emphasized its impact: "We found improved accuracy of data results with TSO 500 v2 compared to our current solution from a different vendor… The solution will also allow us to minimize service costs by consolidating our tests on Illumina sequencers."

Illumina’s latest innovation underscores its commitment to advancing tumour profiling technologies, improving lab efficiency, and supporting the global oncology research community with scalable, high-quality genomic solutions.